Verifying…
Home / Drug A–Z / Vallucam Capsules 20 mg

Vallucam Capsules 20 mg

NAFDAC Reg. No. A4-100612 · Drug

Registered with NAFDAC. Registration activeAs of 27 October 2026 · synced automatically from official sources.
Product
Vallucam Capsules 20 mg
NAFDAC number
A4-100612
Active ingredient
Piroxicam
Strength
20 mg
Form
Capsule
Pack size
10 x 1 x 10's (in PVC-Alu blisters)
Manufacturer
Not listed
Applicant (holder)
A-Nwaeze Pharmaceutical Company Limited
Approved
30 Nov 2023
Status
Active View on NAFDAC ↗
Registration valid to
29 Nov 2028
WHO alerts
None found
Community reports
None
Times checked
0

What we found

  • Vallucam Capsules 20 mg is on the NAFDAC register with an active registration (A4-100612). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

What Vallucam Capsules 20 mg is used for

From the official U.S. FDA label for piroxicam, the active ingredient registered with NAFDAC.

Boxed warning: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions (5.1) ] . …
What it is used for

Piroxicam capsules are indicated: • For relief of the signs and symptoms of osteoarthritis. • For relief of the signs and symptoms of rheumatoid arthritis. Piroxicam capsules are a nonsteroidal anti-inflammatory drug indicated for •Relief of the signs and symptoms of osteoarthritis (OA) ( 1 )•Relief of the signs and symptoms of rheumatoid arthritis (RA) ( 1 )

Possible side effects

The following adverse reactions are discussed in greater detail in other sections of the labeling: • Cardiovascular Thrombotic Events [see Warnings and Precautions (5.1) ] • GI Bleeding, Ulceration and Perforation [see Warnings and Precautions (5.2) ] • Hepatotoxicity [see Warnings and Precautions (5.3) ] • Hypertension [see Warnings and Precautions (5.4) ] • Heart Failure and Edema [see Warnings and Precautions (5.5) ] • Renal Toxicity and Hyperkalemia [see Warnings and Precautions (5.6) ] • Anaphylactic Reactions [see Warnings and Precautions (5.7) ] • Serious Skin Reactions [see Warnings and Precautions (5.9) ] • Hematologic Toxicity [see Warnings and Precautions (5.11) ] Most common adve …

Do not use if

Piroxicam capsules are contraindicated in the following patients: • Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to piroxicam or any components of the drug product [see Warnings and Precautions (5.7 , 5.9) ] • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. …

Warnings

• Hepatotoxicity : Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop ( 5.3 ) • Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure ( 5.4 , 7 ) • Heart Failure and Edema : Avoid use of piroxicam capsules in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure ( 5.5 ) • Renal Toxicity : Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. …

Pregnancy & breastfeeding

8.1 Pregnancy Risk Summary Use of NSAIDs, including piroxicam capsules, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs, including piroxicam capsules, in pregnant women starting at 30 weeks of gestation (third trimester). There are no adequate and well-controlled studies of piroxicam capsules in pregnant women. …

General information only, not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Vallucam Capsules 20 mg

Add the expiry date on your pack for a full Trust Score.

3 free checks left today Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Vallucam Capsules 20 mg

What is in Vallucam Capsules 20 mg?

Vallucam Capsules 20 mg contains Piroxicam (20 mg), as capsule, according to its NAFDAC registration record.

Is Vallucam Capsules 20 mg registered with NAFDAC?

Yes. Vallucam Capsules 20 mg is listed on the NAFDAC register under registration number A4-100612, and its registration is active as of 27 October 2026.

Has Vallucam Capsules 20 mg been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Vallucam Capsules 20 mg in our automatically synced alert list.

How can I check that my pack of Vallucam Capsules 20 mg is genuine?

Run a free authenticity scan with the NAFDAC number A4-100612, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Vallucam Capsules 20 mg used for?

Piroxicam capsules are indicated: • For relief of the signs and symptoms of osteoarthritis. • For relief of the signs and symptoms of rheumatoid arthritis. Piroxicam capsules are a nonsteroidal anti-inflammatory drug indicated for •Relief of the signs and symptoms of osteoarthritis (OA) ( 1 )•Relief of the signs and symptoms of rheumatoid arthritis (RA) ( 1 ) (Summarised from the official U.S. FDA label for piroxicam. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Vallucam Capsules 20 mg? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.